- Home
- BABA vs GILD Comparison
BABA vs GILD Comparison
Compare BABA & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BABA | GILD |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | Hong Kong | United States |
| Employees | 128197 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4B | 173.9B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | BABA | GILD |
|---|---|---|
| Price | $138.64 | $138.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 18 |
| Target Price | ★ $185.15 | $148.39 |
| AVG Volume (30 Days) | ★ 9.4M | 4.9M |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | 0.79% | ★ 2.35% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $5.21 | $4.65 |
| Revenue Next Year | $11.22 | $5.96 |
| P/E Ratio | $21.20 | ★ $20.62 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $107.19 | $95.30 |
| 52 Week High | $192.67 | $157.29 |
Technical Indicators
Market Signals| Indicator | BABA | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 44.68 |
| Support Level | $118.18 | $133.89 |
| Resistance Level | $139.19 | $142.33 |
| Average True Range (ATR) | 3.29 | 3.27 |
| MACD | 2.41 | 0.21 |
| Stochastic Oscillator | 90.16 | 50.88 |
Price Performance
Historical ComparisonAbout BABA Alibaba Group Holding Limited
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).